Clinical Trials
4 trialsNCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT02643550 2023-05-12
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Innate Pharma
Phase 1/2 Completed
NCT02557516 2019-12-17
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
Innate Pharma
Phase 1/2 Terminated
NCT03307941 2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2 Withdrawn